Custom Multi-Analyte Drug Panels: De Novo Bioanalytical Method Development

High-end drug discovery demands more than just equipment; it requires a partner who re-engineers assay chemistry to match the molecule. Our de novo platform is designed to eliminate the common failures of generic assays by focusing on three pillars of bioanalytical depth to ensure your project moves from discovery to development without technical setbacks.

1. Engineered Resolution for Extreme Chemical Diversity

One of the greatest challenges in multi-analyte panels is the simultaneous extraction and ionization of compounds with vastly different polarities (LogP) and pKa values. While generic methods sacrifice the sensitivity of one compound for another, our De Novo Engineering utilizes:

• Custom Gradient Architecture: We design bespoke LC-gradient profiles that ensure sharp peak shapes for both highly polar and hydrophobic molecules. This is vital when scaling from simple Plasma & Serum Drug Quantification to diverse multi-class drug panels.
• Dynamic Polarity Switching: By deploying rapid ESI polarity switching (Positive/Negative) within a single injection, we maximize coverage across diverse chemical classes, ensuring no critical component is "left behind."

2. Systematic Mitigation of Sophisticated Matrix Effects

In high-complexity matrices—such as brain tissue, ocular fluids, or specialized cell lysates—endogenous lipids and proteins cause severe ion suppression. For projects requiring Drug Quantification in Tissue and Cell Lysates, our de novo approach includes:

• Targeted Clean-up Protocols: We engineer tailored solid-phase (SPE) and liquid-liquid extraction (LLE) steps that "strip" the matrix while preserving the chemical integrity of thermally or pH-unstable analytes.
• Quantitative Matrix Assessment: We provide a quantitative matrix factor evaluation for every custom panel, giving you the empirical proof that your data is free from endogenous suppression.

3. Absolute Specificity via MRM Fingerprinting

For polypharmacy studies involving drugs with shared fragment ions, traditional mass spectrometry can suffer from "false positives." Our platform utilizes Scheduled Multiple Reaction Monitoring (sMRM) and Collision Energy (CE) Ramping. This level of specificity is essential when your panel requires High-Resolution Metabolite Quantification to accurately differentiate between a parent drug and its structurally similar metabolites.

We manage the entire analytical lifecycle of your custom panel, ensuring transparent communication and rigorous scientific checkpoints at every stage of the project.

1. Physicochemical Profiling & Feasibility: Analysis of analyte structures to predict solubility, stability, and potential Drug-Drug Interaction (DDI) risks.
2. MRM Transition Engineering: Exhaustive fragmentation mapping to select the most stable precursor-to-product ion pairs, optimizing signal-to-noise ratios.
3. Bespoke Extraction Design: Development of tailored sample preparation protocols (SPE, LLE) to achieve maximum recovery (>85%), providing the foundation for reliable Single Drug Quantification.
4. High-Resolution LC-MS/MS Execution: Execution on premium Triple Quadrupole or Orbitrap platforms, ensuring pg/mL sensitivity.
5. Stringent Accuracy & Precision QC: Validation through intra- and inter-day precision checks using matrix-matched Quality Control (QC) samples.
6. Integrated Scientific Reporting: Delivery of comprehensive data packages linked with Metabolite Identification (MetID) data where applicable.

To ensure the success of de novo development, we provide highly specific sample handling guidelines. For more details, consult our Tissue Bioanalysis Protocol Guide.